Literature DB >> 12476303

Transforming pathways activated by the v-Abl tyrosine kinase.

Scott K Shore1, Ramana V Tantravahi, E Premkumar Reddy.   

Abstract

The Abelson Murine Leukemia Virus (A-MuLV) is the acute transforming retrovirus encoding the v-abl oncogene. Two isolates of the virus encoding proteins of p120 Kd and 160 Kd have been extensively studied. These viral isolates have been found to transform both hematopoietic and fibroblastic cells in vitro, while inducing predominantly pre-B cell leukemias in vivo. Both p120(v-Abl) and p160(v-Abl) are plasma membrane-associated non-receptor tyrosine kinases and the transforming activity of these proteins requires their tyrosine kinase activity. A-MuLV infection of hematopoietic cells has often been found to result in the abrogation of their cytokine-dependence for growth. In addition, v-Abl expressing hematopoietic cells often lose their ability to differentiate in response to appropriate cytokines. This review discusses some of the early transformation studies of A-MuLV, as well as some of the findings concerning the structure and biochemical activity of the v-Abl protein. Finally, we discuss the mechanisms associated with v-Abl mediated transformation through examination of the various signal transduction pathways activated by this oncogene.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12476303     DOI: 10.1038/sj.onc.1206084

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  11 in total

1.  Gag influences transformation by Abelson murine leukemia virus and suppresses nuclear localization of the v-Abl protein.

Authors:  Chae-Ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2007-06-27       Impact factor: 5.103

2.  Plasmacytomagenesis in Eμ-v-abl transgenic mice is accelerated when apoptosis is restrained.

Authors:  Cassandra J Vandenberg; Paul Waring; Andreas Strasser; Suzanne Cory
Journal:  Blood       Date:  2014-07-01       Impact factor: 22.113

Review 3.  Genetically engineered mouse models in cancer research.

Authors:  Jessica C Walrath; Jessica J Hawes; Terry Van Dyke; Karlyne M Reilly
Journal:  Adv Cancer Res       Date:  2010       Impact factor: 6.242

4.  SH2-containing inositol 5'-phosphatase inhibits transformation of Abelson murine leukemia virus.

Authors:  Shawn P Fessler; Naomi Rosenberg; Linda B Baughn
Journal:  J Virol       Date:  2011-06-22       Impact factor: 5.103

5.  Duplication of Subcytoband 11E2 of Chromosome 11 Is Regularly Associated with Accelerated Tumor Development in v-abl/myc-Induced Mouse Plasmacytomas.

Authors:  Francis Wiener; Ann-Kristin Schmälter; Michael R A Mowat; Sabine Mai
Journal:  Genes Cancer       Date:  2010-08

6.  Changes in p19Arf localization accompany apoptotic crisis during pre-B-cell transformation by Abelson murine leukemia virus.

Authors:  Rebekah Stackpole Zimmerman; Naomi Rosenberg
Journal:  J Virol       Date:  2008-06-25       Impact factor: 5.103

7.  Mutations affecting the MA portion of the v-Abl protein reveal a conserved role of Gag in Abelson murine leukemia virus (MLV) and Moloney MLV.

Authors:  Chae-ryun Yi; Naomi Rosenberg
Journal:  J Virol       Date:  2008-03-26       Impact factor: 5.103

8.  MoMuLV-ts-1: A Unique Mouse Model of Retrovirus-Induced Lymphoma Transmitted by Breast Milk.

Authors:  J Chakraborty; H Okonta; H Bagalb; J Duggan
Journal:  Adv Virol       Date:  2011-08-16

9.  C/EBP-Induced Transdifferentiation Reveals Granulocyte-Macrophage Precursor-like Plasticity of B Cells.

Authors:  Branko Cirovic; Jörg Schönheit; Elisabeth Kowenz-Leutz; Jelena Ivanovska; Christine Klement; Nina Pronina; Valérie Bégay; Achim Leutz
Journal:  Stem Cell Reports       Date:  2017-01-19       Impact factor: 7.765

10.  B cell lymphoma in HIV transgenic mice.

Authors:  Sabrina Curreli; Selvi Krishnan; Marvin Reitz; Yanto Lunardi-Iskandar; Mark K Lafferty; Alfredo Garzino-Demo; Davide Zella; Robert C Gallo; Joseph Bryant
Journal:  Retrovirology       Date:  2013-08-28       Impact factor: 4.602

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.